Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salix Pharmaceuticals Ltd.

http://www.salix.com

Latest From Salix Pharmaceuticals Ltd.

Can Roche’s Phesgo Mirror UK Adoption Trend in India?

Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?

Commercial Pricing Strategies

Bausch Investors Initially Pessimistic Following B+L Spinout

With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.

Sales & Earnings Business Strategies

Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business

Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.

Sales & Earnings Business Strategies

D-Day Approaches For Bayer’s Asundexian Phase III Plans

With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.

Sales & Earnings Cardiovascular
See All

Company Information

  • Other Names / Subsidiaries
    • InKine Pharmaceutical
    • Oceana Therapeutics, LLC
    • Q-Med Scandinavia, Inc.
    • Santarus, Inc.
UsernamePublicRestriction

Register